M€ in open calls for proposals for a total Budget of 32.413 M€.
Grants for collaborative R&D Projects involving more than 2 independent entities established in 2 or more EU Member or Associated States, for the development of innovative products, services or processes.

Need funding for your R&D project?

While individually each disease is rare, approximately 1 in 17 people (6-8% of the population) are affected with 50% of diseases having a motor, sensory or intellectual deficiency. Two-thirds of rare diseases are genetic and therefore the recent breakthrough in genome sequencing now enables elucidation of the molecular basis of
diseases, opening the door to new therapeutic approaches. While the EU Orphan Medicinal Products Regulation aims to provide effective therapies to patients with rare disease and incentives to industry to develop these therapies, there remains a need for an integrated approach to understanding the underlying disease mechanisms involved in rare diseases in order to significantly advance the number of therapeutic options available to patients. There is also a need for improving diagnostic and screening approaches to ensure that where therapy is available, it can be administered as early as possible maximising positive prognosis. Furthermore, increased awareness of rare diseases within the general public, health care professionals and clinicians is also required.

Gender', 'age' and 'paediatrics' all define a rather rough stratification of patients. In spite of all progress in biomedical research, there is still a huge therapeutic need in these and other specific sub-groups of the population.